Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03020030Phase 3Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2017
- Primary completion
- Nov 2026
- Modality
- Therapeutic Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Dana-Farber Cancer Institute. Started Mar 2017; status: active, not recruiting.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03020030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020030.